VRXA · Veraxa Biotech AG - Post de-SPAC · Investor Relations

Mr. Willener brings more than three decades of global capital markets and corporate finance experience to support advancement of the Company’s pipeline of potential best-in-class therapies led by its BiTAC® platform Zurich, Switzerland, Sept. 04, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:

Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY, Aug. 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:

First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including click chemistry and conjugation technology.

VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful

ZURICH, SWITZERLAND, July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary General Meeting (EGM) today. All resolutions proposed by the Board of Directors and

ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph Erkel, Ph.D., as Chief Scientific Officer (CSO), effective immediately.

Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial de-risking of the development path for this novel therapeutic modality ZURICH, SWITZERLAND – July

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in

ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds Torsten Bürgermeister.

Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer